3.25
                                            Atea Pharmaceuticals Inc Stock (AVIR) Forecast
The Atea Pharmaceuticals Inc (AVIR) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $12.71, representing a +291.00% increase from the current price of $3.25. The highest analyst price target is $12.81, and the lowest is $12.60.
                Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
        12-Month AVIR Price Target
            
                Average 10.74 
                (+230.40% Upside)
                
                    
                        
                    
                
            
        Is Atea Pharmaceuticals Inc (AVIR) A Buy Now?
Oscillators
                | Name | Value | Action | 
|---|---|---|
| RSI(14) | 56.55 | Neutral | 
| STOCH(9,6) | 73.25 | Neutral | 
| STOCHRSI(14) | 56.84 | Neutral | 
| MACD(12,26) | 0.0453 | Buy | 
| ADX(14) | 13.92 | Neutral | 
| William %R | -28.33 | Neutral | 
| CCI(14) | 11.37 | Neutral | 
                            Buy: 1
                            Sell: 0
                            Neutral: 6
                        
                        Summary: Neutral
                        Moving Averages
                | Period | Simple | Exponential | 
|---|---|---|
| MA10 | 
                                     3.249 
                                        Buy 
                                     | 
                                
                                     3.2307 
                                        Buy 
                                     | 
                            
| MA20 | 
                                     3.1815 
                                        Buy 
                                     | 
                                
                                     3.1864 
                                        Buy 
                                     | 
                            
| MA50 | 
                                     3.152 
                                        Buy 
                                     | 
                                
                                     3.1881 
                                        Buy 
                                     | 
                            
| MA100 | 
                                     3.3365 
                                        Sell 
                                     | 
                                
                                     3.2172 
                                        Buy 
                                     | 
                            
| MA200 | 
                                     3.1627 
                                        Buy 
                                     | 
                                
                                     3.2559 
                                        Sell 
                                     | 
                            
                            Buy: 8
                            Sell: 2
                            Neutral: 0
                        
                        Summary: Buy
                        
                According to our latest analysis, AVIR could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 2 signaling Sell signals and 6 Neutral signals. This might be a good time to open fresh positions on AVIR, as trading bullish markets is always a lot easier
            
            - RSI (Relative Strength Index): The RSI(14) value of 56.55 indicates that AVIR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
 - STOCH (Stochastic Oscillator): The STOCH value of 73.25 indicates that AVIR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
 - STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 56.84 indicates that AVIR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
 - ADX (Average Directional Index): The ADX value of The ADX value of 13.92 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
 - CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 11.37 indicates that AVIR is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
 
Long-term AVIR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Atea Pharmaceuticals Inc financial reports and earnings history, Atea Pharmaceuticals Inc (AVIR) stock could reach $30.41 by 2030, $14.82 by 2040 and $116.68 by 2050. See the projected annual prices until 2050 of the Atea Pharmaceuticals Inc stock below:
- Atea Pharmaceuticals Inc (AVIR) is expected to reach an average price of $30.68 in 2035, with a high prediction of $32.16 and a low estimate of $30.83. This indicates an $844.10% rise from the last recorded price of $3.25.
 - Atea Pharmaceuticals Inc (AVIR) stock is projected to chart a bullish course in 2040, with an average price target of $13.76, representing an $323.50% surge from its current level. The forecast ranges from a conservative $14.11 to a sky-high $14.82.
 - Our analysts predict Atea Pharmaceuticals Inc (AVIR) to jump 3,481% by 2045, soaring from $116.58 to an average price of $116.38, potentially reaching $117.21. While $116.58 is the low estimate, the potential upside is significant.
 - Atea Pharmaceuticals Inc (AVIR) stock is expected to climb by 2050, reaching an average of $113.26, a $3,385% jump from its current level. However, a wide range of estimates exists, with high and low targets of $116.68 and $113.42, respectively, highlighting the market's uncertainty.
 
Atea Pharmaceuticals Inc Stock (AVIR) Year by Year Forecast
Atea Pharmaceuticals Inc Stock (AVIR) Price Forecast for 2025
                                Atea Pharmaceuticals Inc Stock (AVIR) is expected to reach an average price of $11.91 in 2025, with a high prediction of $23.48 and a low estimate of $0.3337. This indicates an +266.34% rise from the last recorded price of $3.25.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| December, 2025 | $13.27 | $12.60 | $12.81 | +308.39% | 
Atea Pharmaceuticals Inc Stock (AVIR) Price Forecast for 2026
                            The predicted value for Atea Pharmaceuticals Inc (AVIR) in 2026 is set at an average of $10.67. Estimates vary from a peak of $12.68 to a trough of $8.6631, indicating an +228.40% surge from the present price of $3.25.
                        
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2026 | $10.44 | $11.47 | $12.68 | +221.31% | 
| February, 2026 | $11.60 | $10.56 | $10.59 | +257.01% | 
| March, 2026 | $9.6729 | $10.55 | $10.55 | +197.63% | 
| April, 2026 | $8.5231 | $8.8231 | $8.883 | +162.25% | 
| May, 2026 | $8.9632 | $8.6631 | $8.6632 | +175.79% | 
| June, 2026 | $10.20 | $9.1832 | $9.7733 | +213.95% | 
| July, 2026 | $9.2435 | $9.4635 | $10.14 | +184.41% | 
| August, 2026 | $10.03 | $9.3035 | $9.8736 | +208.73% | 
| September, 2026 | $9.4838 | $9.7738 | $9.8436 | +191.81% | 
| October, 2026 | $8.6539 | $8.8939 | $9.1038 | +166.27% | 
| November, 2026 | $8.824 | $8.674 | $8.5839 | +171.51% | 
| December, 2026 | $9.0441 | $8.884 | $8.9541 | +178.28% | 
Atea Pharmaceuticals Inc Stock (AVIR) Price Forecast for 2027
                                For 2027, Stockscan's Analyst expects the average price target for Atea Pharmaceuticals Inc (AVIR) is $5.2595, with a high forecast of $8.6142 and a low forecast of $1.9048. This indicates an +61.83% increase from the last price of $3.25.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2027 | $8.4543 | $8.5893 | $8.6142 | +160.13% | 
| February, 2027 | $7.9944 | $8.1444 | $8.1743 | +145.98% | 
| March, 2027 | $6.1945 | $6.5045 | $7.7494 | +90.60% | 
| April, 2027 | $6.4347 | $6.4311 | $6.2297 | +97.99% | 
| May, 2027 | $6.2548 | $6.1747 | $6.2538 | +92.45% | 
| June, 2027 | $5.6949 | $5.7049 | $6.0548 | +75.23% | 
| July, 2027 | $5.305 | $5.385 | $5.45 | +63.23% | 
| August, 2027 | $4.9352 | $5.0152 | $5.0851 | +51.85% | 
| September, 2027 | $4.4153 | $4.4103 | $4.7552 | +35.86% | 
| October, 2027 | $3.6754 | $3.8454 | $4.0953 | +13.09% | 
| November, 2027 | $3.2256 | $3.2256 | $3.5155 | -0.75% | 
| December, 2027 | $1.4657 | $1.9048 | $2.8856 | -54.90% | 
Atea Pharmaceuticals Inc Stock (AVIR) Price Forecast for 2028
                                In 2028, Atea Pharmaceuticals Inc (AVIR) is projected to reach an average price of $18.72, with a high projection of $37.43 and a low estimate of $0.0138. This indicates an +476.10% rise from the last price of $3.25.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2028 | $0.9058 | $1.1058 | $1.2307 | -72.13% | 
| February, 2028 | $0.5759 | $0.5259 | $0.4059 | -82.28% | 
| March, 2028 | $0.2161 | $0.2655 | $0.321 | -93.35% | 
| April, 2028 | $26.47 | $0.0138 | $25.05 | +714.46% | 
| May, 2028 | $29.97 | $26.68 | $26.17 | +822.16% | 
| June, 2028 | $16.36 | $23.80 | $28.83 | +403.40% | 
| July, 2028 | $15.74 | $5.2733 | $17.16 | +384.28% | 
| August, 2028 | $4.0189 | $1.3989 | $37.43 | +23.66% | 
| September, 2028 | $6.8287 | $0.4588 | $24.05 | +110.11% | 
| October, 2028 | $17.47 | $1.7864 | $8.7186 | +437.59% | 
| November, 2028 | $32.16 | $29.42 | $29.85 | +889.60% | 
| December, 2028 | $27.73 | $29.04 | $30.61 | +753.30% | 
Atea Pharmaceuticals Inc Stock (AVIR) Price Forecast for 2029
                                The 2029 price forecast for Atea Pharmaceuticals Inc Stock (AVIR) is $21.95 on average, with a high prediction of $36.70 and a low estimate of $7.203. This represents an +575.49% increase from the previous price of $3.25.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2029 | $25.13 | $27.86 | $27.57 | +673.30% | 
| February, 2029 | $19.54 | $22.44 | $23.72 | +501.31% | 
| March, 2029 | $19.56 | $19.21 | $18.14 | +501.93% | 
| April, 2029 | $5.1357 | $7.203 | $18.90 | +58.02% | 
| May, 2029 | $35.01 | $7.5532 | $33.59 | +977.34% | 
| June, 2029 | $36.69 | $35.05 | $36.70 | +1,029% | 
| July, 2029 | $34.63 | $35.43 | $36.27 | +965.66% | 
| August, 2029 | $35.64 | $34.79 | $35.59 | +996.74% | 
| September, 2029 | $35.48 | $35.05 | $35.04 | +991.83% | 
| October, 2029 | $33.02 | $34.62 | $34.71 | +916.15% | 
| November, 2029 | $32.40 | $32.26 | $32.34 | +897.08% | 
| December, 2029 | $32.51 | $32.38 | $32.00 | +900.16% | 
Atea Pharmaceuticals Inc Stock (AVIR) Price Forecast for 2030
                                Atea Pharmaceuticals Inc Stock (AVIR) is expected to reach an average price of $25.88 in 2030, with a high forecast of $30.41 and a low forecast of $21.36. This signifies an +696.36% surge from the last price of $3.25.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2030 | $28.93 | $29.24 | $30.41 | +790.02% | 
| February, 2030 | $28.59 | $28.80 | $28.70 | +779.56% | 
| March, 2030 | $26.65 | $26.81 | $28.12 | +719.88% | 
| April, 2030 | $25.37 | $25.47 | $26.07 | +680.50% | 
| May, 2030 | $25.60 | $25.47 | $25.17 | +687.59% | 
| June, 2030 | $26.02 | $26.15 | $25.78 | +700.52% | 
| July, 2030 | $24.80 | $24.42 | $25.27 | +662.99% | 
| August, 2030 | $24.13 | $24.36 | $24.60 | +642.38% | 
| September, 2030 | $23.08 | $23.71 | $23.72 | +610.08% | 
| October, 2030 | $21.96 | $22.06 | $22.65 | +575.63% | 
| November, 2030 | $21.88 | $21.79 | $21.55 | +573.17% | 
| December, 2030 | $20.74 | $21.36 | $21.60 | +538.10% | 
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):